New schizophrenia drug candidate passes early safety check
NCT ID NCT01879722
First seen May 12, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This early-stage study tested TAK-063, an experimental drug, in 77 people (some with stable schizophrenia, some healthy Japanese volunteers). The main goal was to see if the drug is safe and how the body processes it at different doses. No major claims about effectiveness were made; the focus was purely on safety and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Glendale, California, United States
Conditions
Explore the condition pages connected to this study.